EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS

EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS

Background: Cirrhosis is a major cause of mortality and morbidity worldwide. It is also a frequent cause of hospital admissions. The objective of this study was to determine the efficacy of rifaximin and lactulose versus lactulose alone for the treatment of hepatic encephalopathy. Material & M...

Full description

Bibliographic Details
Main Authors:	Hafsa Habib, Dur-e- Nayab, Zafar Hayat, Shahid Jamil, Habibullah Khan
Format:	Article
Language:	English
Published:	Gomal Medical College, D.I.Khan, Pakistan 2016-12-01
Series:	Gomal Journal of Medical Sciences
Subjects:	liver cirrhosis rifaximin lactulose hepatic encephalopathy.
Online Access:	http://gjms.com.pk/ojs24/index.php/gjms/article/view/1381

Similar Items

Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan
by: Ching Chang, et al.
Published: (2021-05-01)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
by: Wang Z, et al.
Published: (2018-12-01)

Managing Hepatic Encephalopathy - Combination of Lactulose and Rifaximin Versus Lactulose Monotherapy: A meta-analysis
by: Saad Khalid, et al.
Published: (2024-04-01)

Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy
by: Igor G. Bakulin, et al.
Published: (2023-10-01)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
by: Yasuyuki Tamai, et al.
Published: (2021-07-01)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
by: Ming-Wei Wang, et al.
Published: (2023-03-01)

A comparative study to determine the short-term mortality and clinical improvement in hepatic encephalopathy using either rifaximin and or lactulose
by: Uttam Biswas, et al.
Published: (2021-03-01)

Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy
by: Simona Parisse, et al.
Published: (2023-10-01)

Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose
by: Praveen Sharma, et al.
Published: (2011-01-01)

Hepatic encephalopathy: current challenges and future prospects
by: Swaminathan M, et al.
Published: (2018-03-01)

Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
by: Hideto Kawaratani, et al.
Published: (2022-03-01)

Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis
by: Guihua Fang, et al.
Published: (2024-03-01)

Minimal Hepatic Encephalopathy in Cirrhosis- How Long to Treat?
by: Omesh Goyal, et al.
Published: (2017-01-01)

Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial
by: Mohammadreza Naderian, et al.
Published: (2017-01-01)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
by: Xiao Yu, et al.
Published: (2022-01-01)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
by: Torre A, et al.
Published: (2023-10-01)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
by: Alba Mangas-Losada, et al.
Published: (2019-08-01)

Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy
by: Xianghui Han, et al.
Published: (2021-10-01)

Hepatic encephalopathy in clinical practice: diagnosis and treatment
by: T. N. Lopatkina, et al.
Published: (2013-12-01)

Comparison of polyethylene glycol 3350 electrolyte solution and lactulose in patients with overt hepatic encephalopathy: A retrospective study from a tertiary care hospital
by: Beg MA, et al.
Published: (2022-10-01)

Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial
by: Kapil Sharma, et al.
Published: (2014-01-01)

Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis
by: Asmaa N Mohammad, et al.
Published: (2018-01-01)

Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy
by: Fulvio Pandico, et al.
Published: (2023-07-01)

Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study
by: Takao Miwa, et al.
Published: (2022-12-01)

Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites
by: Keiji Yokoyama, et al.
Published: (2022-09-01)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
by: Leon Louis Seifert, et al.
Published: (2021-10-01)

The Role of Presepsin in Diagnosing Infections in Patients with Liver Cirrhosis and Overt Hepatic Encephalopathy
by: Razvan Igna, et al.
Published: (2022-08-01)

An evidence-based update on hepatic encephalopathy
by: Abdo Ayman
Published: (2006-01-01)

Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy
by: Ahmad Shavakhi, et al.
Published: (2014-01-01)

Visión actual sobre el diagnóstico y los cuidados integrales en la encefalopatía hepática
by: F. Higuera-de-la-Tijera, et al.
Published: (2023-04-01)

Serum S100B Levels in Patients with Liver Cirrhosis and Hepatic Encephalopathy
by: Mo-Jong Kim, et al.
Published: (2023-01-01)

Assentment of the influence of liver cirrhosis and minimal hepatic encephalopathy on quality of life
by: Diana Santos, et al.
Published: (2014-06-01)

The Relationship of Plasma Zinc Concentration and Hepatic Encephalopathy in Patients with Cirrhosis
by: Rahmatollah Rafiei, et al.
Published: (2014-11-01)

Predictors of minimal hepatic encephalopathy in patients with cirrhosis
by: Sharma Praveen, et al.
Published: (2010-01-01)

Frequency of H. pylori in liver cirrhosis patients with overt Hepatic encephalopathy at tertiary care hospital, Karachi.
by: Shaista Ahmed, et al.
Published: (2022-07-01)

Overview of Serum Interleukin-18 (IL-18) Levels in Liver Cirrhosis Patients and Their Correlation to Hepatic Encephalopathy
by: Anton Komala, et al.
Published: (2018-08-01)

NUTRITIVE THERAPY OF HEPATIC ENCEPHALOPATHY AS A COMPLICATION OF LIVER CIRRHOSIS
by: Bojana Marković-Živković, et al.
Published: (2012-06-01)

Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement)
by: M. Yu. Nadinskaia, et al.
Published: (2024-03-01)

Early mechanical ventilation for grade IV hepatic encephalopathy is associated with increased mortality among patients with cirrhosis: an exploratory study
by: Saad Saffo, et al.
Published: (2022-08-01)

Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis
by: Mohammed M. Shamseya, et al.
Published: (2016-09-01)